

## **EISAI RECEIVES EUROPEAN COMMISSION APPROVAL ON USE OF ANTIEPILEPTIC AGENT ZONEGRAN® IN PEDIATRIC PATIENTS**

Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") announced today that it has received approval from the European Commission (EC) on the license extension application submitted by its U.K. subsidiary Eisai Ltd. regarding the use of antiepileptic agent Zonegran® (zonisamide) in the treatment of pediatric patients. The approval extends the use of adjunctive Zonegran in the treatment of partial seizures (with or without secondary generalization) by changing the approved age range from adults aged 18 years and above to now also include pediatric patients aged 6 years and above.

Zonegran is an antiepileptic drug (AED) original

**[Notes to editors]**

**1. About Zonegran® (zonisamide) Study 312**